Newly developed retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable buzz within the medical community. Preliminary clinical studies have demonstrated impressive decreases in physical mass and gains in health markers for people with overweight. Experts believe this novel approach could signi